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ABSTRACT 
Objective: The present study was designed to study the anticancer activity of a series of novel analogs of phenothiazine with dithiocarbamate as a 
side chain. 
Methods: A novel series of derivatives containing dithiocarbamate as a side chain at the tenth position of phenothiazine nucleus were synthesized, 
characterized by spectral analysis, and evaluated for their antimitotic and antioxidant activity using germinated Bengal gram seeds and 2,2-
diphenyl-1-picrylhydrazyl (DPPH) method, respectively. A quantitative estimate of drug-likeness was also performed, which calculated the 
molecular properties and screened the molecules based on drug-likeness rules. Further, molecular docking study was performed for finding the 
binding affinity with tubulin protein to rationalize their anticancer activity. 
Results: The results revealed that the antioxidant activity of compounds 3e, 3g, 3i, 3j and standard Ascorbic acid were 10 mmol, 14 mmol, 16 mmol, 
16 mmol and 35 mmol, respectively. Further compounds 3e, 3g, 3h and 3i have shown promising antimitotic activity. Compound 3i (-9 K. Cal/mol) 
showed the highest binding energies towards tubulin protein when compared to standard drug colchicine (-8.6 K. Cal/mol). Among all, compound 3i 
showed promising antimitotic and antioxidant activity, which correlated with insilico docking studies. 
Conclusion: Dithiocarbamate substituted phenothiazine derivatives proved to be encouraging leads as tubulin inhibitors. 
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INTRODUCTION 
In recent years, the design and synthesis of novel bioactive compounds 
gained significant applications in the pharmaceutical industries. 
Phenothiazine ring systems are of considerable interest as it is a core 
structure in various synthetic pharmaceuticals displaying a broad 
spectrum of biological activities including tranquilizers, anti-
inflammatory, antimalarial, anti-psychotropic, antimicrobial, 
antitubercular, antitumor, antihistamine and analgesic properties [1-
3]. Moreover, phenothiazine derivatives having an acyl side chain 
playing a crucial role in anticancer activity. Other side 
dithiocarbamates have exhibited colossal pharmacological activities; 
especially the sulfur atom in dithiocarbamate possesses strong 
nucleophilic and redox properties. Several literature reports indicate 
inclusion of dithiocarbamate as a linker or side chain in active 
pharmacophore improves the overall biological profile [4-7]. Fig. 1 
represents the natural products and marketed drugs mostly contain 
dithiocarbamate moiety [8]. Inspired by these findings, we designed 
novel dithiocarbamate substituted N-acyl phenothiazine derivatives as 
anticancer agents. 
ComputerAided Drug Design (CADD) is a widely used term that 
represents computational tools, resources for the storage, 
management, analysis, and modeling of compounds [9]. An ideal 
computational method for lead discovery should be able to generate 
structurally diverse leads and should give an estimate of binding 
affinities that would correlate with experimental values. The 
molecular structure is based on physicochemical, drug metabolism, 
pharmacokinetics (DMPK), and toxicity properties [10]. High oral 
bioavailability is a vital consideration for the development of 
bioactive molecules as therapeutic agents. Therefore, the 
bioavailability-related prediction of properties such as solubility, 
lipophilicity, good drug absorption, low polar surface area, the sum 
of hydrogen bond donors and acceptors, molecular weight, partition 
coefficient (LogP) are vital before actual synthesis to reduce the 
chemical expenses and precious time. The molecular properties of 
compounds can be calculated using Molinspiration [11], Molsoft 
[12], Osiris [13], pKCSM [14], and Swiss Absorption Distribution 
Metabolism and Excretion (ADME) [15] software which help to 
reduce cost, late-stage failures and hasten the successful 
development of new molecular moieties. 
Molecular docking may be defined as an optimization problem, 
which would outline the best-fit orientation of a ligand that binds to 
a particular protein of interest and is used to expect the structure of 
the intermolecular complex formed between two or more molecules.  
The current study incorporates the use of insilico molecular 
modeling tool Auto dock Vina [16]. The receptor grid that was 
generated will helps in locating the protein active site and preparing 
the grid for the ligands to be docked in the shape and properties of 
the receptor are represented on a grid by many different sets of 
fields that provide progressively more precise scoring of the ligand 
poses. The binding energies of mentioned analogs further clarify the 
design of potential drug candidates against tubulin protein. 
MATERIALS AND METHODS 
All chemicals were purchased from Aldrich and Merck and were 
used without further purification. The Melting points were obtained 
on the Lab India Digital Melting Point instrument and are 
uncorrected. Infrared spectra were recorded on the ALPHA Bruker 
instrument and values are given in cm-1. 1H NMR spectra were 
recorded in CDCl3 on a Bruker Ux-NMR instrument using methyl 
silane (Me4Si) as the internal standard. High-Resolution Mass 
Spectroscopy (HRMS) was recorded on maXis 10138. Each reaction 
was monitored by using an appropriate solvent system, which was 
selected by trial and error method on Pre-coated Thin Layer 
Chromatography (TLC) plates (0.25 mm silica gel) were obtained 
from E. Merck and visualized with Ultra Violet (U. V) light. Column 
chromatography was performed on Silica gel 60-120 mesh (Merck) 
using commercially available petroleum ether and ethyl acetate. 
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Fig. 1: Natural products and marketed drugs containing dithiocarbamate moiety 
 
Antioxidant activity of the synthesized compounds was performed by 
the 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging method 
[17]. The experiment was carried out at the concentration of 5, 10, 15, 
20, 25, µg/ml in methanol, using ascorbic acid as standard. Results are 
shown in table 3 and expressed as mmol. The compound 3e (benzyl 
derivative), showed the best potency, while compound 3g (pyrrolidine 
derivative) 3i (methyl piperazine derivative), and 3j (ethyl piperazine) 
showed a slight reduction of antioxidant activity. The compound 3h 
(piperidine derivative) was equipotent with the standard ascorbic 
acid. The remaining all compounds showed weak activity.  
The title compounds 3a-k were screened for their in vitro antimitotic 
activity [18] using germinated Bengal gram seeds and methanol in a 
control group 
The molecular docking was performed using AUTO DOCK Vina 
software installed on a single machine running on an Intel Core i5-
3317U CPU @ 1.70 GHz Processor with 6 GB RAM and Windows7 with 
64-bit Operating System [19]. With a known biological target named 
tubulin (PDB ID:-1SA0) for phenothiazine substituted dithiocarbamate 
compounds. A grid was generated around the co-crystallized ligand. 
The coordinates (x = 116.98, y = 90.11, z = 8.392) were generated with 
the help of MGL Tools and Pharmit: interactive exploration of chemical 
space (http://pharmit. csb. pitt. edu/). Prepared pdbqt files for both 
target and ligands. The created inhouse batch file of ligands and target 
and docking was performed in the absence of water molecules for all 
12 molecules (11+1 standard drug). The molecules were analyzed 
after docking and visualized in the discovery studio for the 
interactions with the active site amino acids [20].  
Synthetic procedures 
Dithiocarbamate substituted N-acyl phenothiazine-derivatives were 
synthesized in two steps as shown in scheme 1. In the first step, 
Phenothiazine (1 equiv) in the presence of dry benzene 20 ml, 
treated with chloroacetylchloride (2 equiv) at 0-5° and refluxed for 
3-4 h at 50-60 °C temperature. 
In the second step, an equimolar mixture of appropriate amine and 
anhydrous potassium carbonate in dimethylformamide was stirred 
at room temperature for 5 min, and then carbon disulfide (2 equiv) 
was added. The reaction mixture was stirred for an additional 20 
min, and then appropriate 2-chloro-1-(10H-phenothiazin-10-
yl)ethan-1-one (1 equiv) was added. Stirring was continued at room 
temperature until the reaction was completed as monitored by Thin 
Layer Chromatography (TLC). The mixture was poured into cold 
water, extracted with ethyl acetate (3x30 ml); the organic phase was 
washed once more with water and dried with sodium sulfate, and 
filtered. The solvent was evaporated under reduced pressure and 
the resultant residue was purified by chromatography over silica gel 
using a mixture of petroleum ether and ethyl acetate as a solvent to 
give the desired compounds 3a-k. 
 
 
Scheme 1: Synthesis of dithiocarbamate substituted N-acyl phenothiazine derivatives 
 
Synthesis of target derivatives 3a-3k 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethylmethyl-
carbamodithioate: (3a) 
Yield (62.5%); MP 180-182 °C; IR(FT-IR-cm-1) 3334.59(N-H), 3067.71 
(aromatic C-H), 2913.27 (aliphatic C-H), 1692.65 (C=O), 1592.99 
(aromatic C=C),1442.20 (C=S), 1302.40 (C-N); 1H NMR[CDCl3-400MHz] 
δ(ppm) 2.42 (s,3H,CH3), 4.27 (s,2H,CH2), 6.47-7.27 (m,8H,Ar-H); HRMS 
calculated for C16H14N2S3O [M+1]: 346.03, found: 346.01.  
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 
ethylcarbamodithioate: (3b) 
Yield (70.5%); MP 182-184 °C; IR(FT-IR-cm-1) 3335.77(N-H), 
3057.05 (aromatic C-H), 2923.06 (aliphatic C-H), 1643.94 (C=O), 
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1567.02 (aromatic C=C), 1442.28 (C=S), 1303.17 (C-N); 1H 
NMR[CDCl3-400MHz] δ(ppm)2.25-2.45 (t,3H, CH2CH3), 2.75-2.95 (q, 
2H, CH2CH3), 3.51 (s, 2H,CH2), 6.45-7.0 (m, 8H, Ar-H); HRMS 
calculated for C17H16N2S3O [M+1]: 360.04, found: 360.03. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl propan-2-
ylcarbamodithioate: (3c) 
Yield (75%); MP 180-182 °C; IR(FT-IR-cm-1) 3337.75(N-H), 
3031.56 (aromatic C-H), 2948.49 (aliphatic C-H), 1644.77(C=O), 
1592.55(aromatic C=C), 1442.01 (C=S), 1302.35 (C-N); 1H 
NMR[CDCl3-400MHz] δ(ppm)1.53-1.56 (d,6H,2CH3), 3.33-3.39 
(m,1H,CH), 4.27 (s,2H,CH2), 5.82 (s,1H,NH),26.55-7.26 (m, 8H, 
Ar-H); HRMS calculated for C18H18N2S3O [M+1]: 374.06, found: 
374.08. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 
butylcarbamodithioate: (3d) 
Yield (68%); MP 184-186 °C; IR(FT-IR-cm-1) 3338.64 (N-H), 
3042.65 (aromatic C-H), 2956.49 (aliphatic C-H), 1641.06 (C=O), 
1593.37 (aromatic C=C),1441.92 (C=S), 1302.45(C-N); 1H 
NMR[CDCl3-400MHz] δ(ppm)1.72-1.79 (t,3H, NH 
CH2CH2CH2CH3), 2.52-2.59 (m,4H, NH CH2CH2CH2CH3), 3.15-3.20 
(t,2H,NH CH2CH2CH2CH3), 4.21 (s,2H,CH2S),S7.32-7.82 
(m,8H,ArH), 9.46 (s, 1H, NH); HRMS calculated for C 19H20N2S3O 
[M+1]: 388.09, found: 388.06. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 
benzylcarbamodithioate: (3e) 
Yield (75%); MP 178-180 °C; IR(FT-IR-cm-1) 3336.49 (N-H),3022.04 
(aromatic C-H), 2914.81 (aliphatic C-H), 1668.87 (C=O), 1567.46 
(aromatic C=C), 1441.60 (C=S), 1301.82 (C-N); 1H NMR[CDCl3-
400MHz] δ(ppm)2.24 (s,2H,CH2), 4.21 (s,2H,CH2), 5.81 (s,1H,NH), 
6.54-7.26 (m,13H,ArH); HRMS calculated for C22H18N2S3O [M+1]: 
422.06, found: 422.04. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 1H-
pyrrole-1-carbodithioate: (3f) 
Yield (65.5%); MP 176-178 °C; IR(FT-IR-cm-1) 3053.50 
(Aromatic C-H), 2915.05 (Aliphatic C-H), 1691.43 (C=O), 1421.31 
(C=S),1236.34 (C-N); 1H NMR[CDCl3-400MHz] δ(ppm)2.09-2.12 
(t, 2H, Pyrrole) 3.15-3.24 (d, 2H, pyrrole), 4.14 (s,2H,CH2S),,7.27-
7.82 (m, 8H, ArH); HRMS calculated for C19H14N2S3O [M+1]: 
382.05, found: 382.02. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 
pyrrolidine-1-carbodithioate: (3g) 
Yield (76.8%); MP 180-182 °C; IR(FT-IR-cm-1) 3070.41 (aromatic C-
H), 2910.76 (aliphatic C-H), 1682.13 (C=O), 1436.73 (C=S), 1156.87 
(C-N); 1H NMR[CDCl3-400MHz] δ(ppm)1.25-1.32 (m, 4H, N(CH2)2 
(CH2)2 of pyrolidine), 3.25-3.97 (t, 4H, N(CH2)2 (CH2)2 of pyrolidine), 
4.40 (s,2H,CH2S), 7.28-7.82 (m, 8H, Ar H); HRMS calculated for 
C19H18N2S3O [M+1]: 386.06, found: 386.07. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 
piperidine-1-carbodithioate: (3h) 
Yield (68%); MP 174-176 °C; IR(FT-IR-cm-1) 3052.79 (aromatic C-
H), 2945.61 (aliphatic C-H), 1676.84(C=O), 1426.32(C=S), 
1228.72(C-N); 1H NMR[CDCl3-400MHz] δ(ppm) 4.16 (s,2H,CH2S), 
4.10-4.39 (m,10H,N(CH2)5),7.22-7.67 (m,8H,ArH); HRMS calculated 
for C20H20N2S3O [M+1]: 400.07, found: 400.08.  
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 4-
methylpiperazine-1-carbodithioate: (3i) 
Yield (72%); MP 176-178 °C; IR(FT-IR-cm-1) 3063.92 (aromatic C-
H), 2920.94 (aliphatic C-H), 1685.32 (C=O), 1427.99 (C=S), 1227.43 
(C-N); 1H NMR[CDCl3-400MHz] δ(ppm) 2.15 (s,3H,NCH3),2.25-2.96 
(t,4H, piperazine), 3.22-3.83 (t,4H,piperazine), 4.36 (s,2H,CH2S), 
7.11-7.60 (m, 8H,ArH); HRMS calculated for C20H21N3S3O [M+1]: 
415.08, found: 415.07. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 4-
ethylpiperazine-1-Carbodithioate: (3j) 
Yield (79%); MP 178-180 °C; IR(FT-IR-cm-1) 3079.15 (aromatic C-
H), 2964.55 (aliphatic C-H), 1676.07 (C=O), 1460.70 (C=S), 1232.03 
(C-N); 1H NMR[CDCl3-400MHz] δ(ppm)1.82-1.89 (t,3H, 
NCH2CH3),2.12-2.18 (q,2H,NCH2CH3), 2.15-2.86 (t,4H,piperazine), 
3.12-3.73(t,4H,piperazine), 3.83 (s,2H,CH2ArH), 4.46 (s,2H,CH2S), 
7.15-7.62 (m,8H,ArH); HRMS calculated for C21H23N3S3O [M+1]: 
429.10, found: 429.13. 
Synthesis of 2-oxo-2-(10H-phenothiazin-10-yl) ethyl 
morpholine-4-carbodithioate: (3k) 
Yield (68%); MP 180-182 °C; IR(FT-IR-cm-1) 3010.49 (aromatic C-
H), 2949.70 (aliphatic C-H), 1673.08 (C=O), 1460.37 (C=S), 1228.18 
(C-N); 1H NMR[CDCl3-400MHz] δ(ppm)3.48-4.42 (t,8H,(CH2)4), 3.73 
(s,2H,CH2S), 7.23-7.67 (m,8H,ArH); HRMS calculated for 
C19H18N2S3O2 [M+1]: 402.07, found: 402.05. 
RESULTS AND DISCUSSION 
The synthesis of title compounds obtained by reaction of 
dithiocarbamate with N-(2-chloro-acetyl) phenothiazine in the 
presence of anhydrous Potassium Carbonate (K2CO3) using various 
amines as shown in (scheme). The chemical structures of the newly 
synthesized compounds were characterized by infrared (IR), proton 
nuclear magnetic resonance (1H NMR), and mass analysis. 
In silico experiments 
The knowledge of absorption, distribution, metabolism, excretion 
and toxicity (ADMET) are primary requests for the development of 
new drugs. Lipinski et al. proposed the rule of five, indicating that 
orally active drugs should have a molecular weight is ≤ 500, log p ≤5, 
the number of Hydrogen bond donors is ≤ 5 and the number of 
Hydrogen bond acceptors is ≤ 10 [21]. Additionally, Veber et al. 
proposed that molecular flexibility indicated by rotatable bond 
count ≤ 10 and polar surface area is ≤ 140 °A are important for oral 
bioavailability in the rat [22]. 
In this study Molsoft, Molinspiration, Swiss ADME and Pkcsm were 
used to evaluate pharmacokinetic parameters of all the compounds 
shown in table 1. It was found that there is a zero violation of the 
Lipinski rule, all showed NRTOB between 4 to 7 and TPSA values 
ranged between 20 to 24, an indication for oral absorption. The 
molsoft program was used to evaluate the drug likeliness model 
score. Compounds showing positive drug likeliness model scores are 
recognized as drug-like and can behave as drug molecules. All 
predicted compounds showed drug-like properties. 
The pharmacokinetic parameters were performed using swiss 
ADMET software, Human Intestinal Absorption (HIA), human colon 
adenocarcinoma (CaCO2) permeability coefficient, Blood-brain 
barrier (BBB) shown in table 2. All compounds showed high HIA 
values (92.01-96.70 %) indicating very well absorbed and they 
showed low BBB penetration capacity(0.153–0.288). P-glycoprotein 
(P-gp) acts as a physiological barrier by ejecting drugs and other 
compounds out of cells, which was found to be one of the reasons for 
its resistance to various chemotherapeutics for cancer. Inhibition of 
p-gp results in better bioavailability of the liable drug. Inhibition of 
Cyt.450 iso-forms results in drug-drug interactions. 
Anti-oxidant activity 
According to the results obtained with the DPPH method, the 
antioxidant activity was increased when introducing aromatic ring 
or alicyclic moiety on dithiocarbamate and reduced with aliphatic 
hydrocarbon.  
Anti-mitotic activity 
Results are illustrated in table 3 and expressed as mmol. Among the 
series compounds, 3e and 3g showed maximum inhibition. The 
activity was slightly reduced for compounds 3h, 3i, and 3j the 
activity was reduced slightly. The remaining all compounds showed 
moderate to weak antimitotic activity. 
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Table 1: Molecular properties of 3 (a-k) 
Comp MW MP ( °C)  logP HBD  HBA  Rot B PSA  DLMs BBB 
3a 346.03 180-182  3.71 4 1 4 24.39 0.14 0.187 
3b 360.04 182-184  4.26 4 1 5 23.87 0.20 0.172 
3c 374.06 180-182  4.60 4 1 5 23.22 0.34 0.197 
3d 388.07 184-186  5.22 4 1 7 24.08 0.20 0.127 
3e 422.06 178-180  5.43 4 1 6 23.97 0.09 0.216 
3f 382.03 176-178  4.59 4 0 4 16.90 0.02 0.211 
3g 386.06 180-182  4.68 4 0 4 16.80 0.32 0.268 
3h 400.07 174-176  5.04 4 0 4 16.43 0.42 0.251 
3i 415.08 176-178  3.78 5 0 4 19.91 1.19 0.288 
3j 429.10 178-180  4.27 5 0 5 19.97 1.18 0.319 
3k 402.05 180-182  3.73 5 0 4 24.34 0.22 0.153 
MW-Molecular weight, HBD–No. of hydrogen bond donors, HBA–No. of hydrogen bond acceptors, Rot B–No. of rotatable bonds, PSA–Polar surface 
area, DLMS–Drug likeliness model score, BBB–blood-brain barrier. 
 
Table 2: ADME properties of compounds of 3 (a-k) 
 3a 3b 3c 3d 3e 3f 3g 3h 3i 3j 3k 
 Absorption Intestinal 
(% absorbed) 




93.285 93.57 93.151 94.961 
Substrate Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
P-glycoprotein (P-gp) inhibitor 
P-gp I Yes  Yes  Yes Yes Yes Yes Yes Yes Yes Yes Yes 
P-gp II Yes  Yes  Yes Yes Yes Yes Yes Yes Yes Yes Yes 
 Distribution VDss (Human) 
(log L/kg) 
0.693 0.775 0.82 0.97 0.625 0.635 1.047 1.094 1.499 1.593 0.806 
BBB permeability 
(log BB) 
0.187 0.172 0.197 0.127 0.261 0.211 0.268 0.251 0.288 0.319 0.153 
CNS permeability 
(log PS) 




-1.494 -1.812 -1.85 -1.539 
Metabolism Substrate CYP2D6 No No No No Yes No No No No No No 
CYP3A4 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Inhibitor CYP1A2 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
CYP2C19 Yes Yes Yes Yes Yes Yes Yes Yes No No Yes 
CYP2C9 Yes Yes Yes Yes Yes Yes No No No No No 
CYP2D6 No No No No No No No No No No No 
CYP3A4 No No No Yes Yes Yes No No No Yes No 
Excretion (TC) Log ml/min/kg 0.186 0.12 0.045 0.179 0.037 0.083 0.213 0.164 0.1 0.142 0.56 
Toxicity MTD (log mg/kg/day) 0.027 0.102 0.216 0.297 0.323 -0.183 -0.229 -0.223 -0.174 -0.098 -0.407 
LD50 (mol/kg) 2.871 2.93 2.843 2.947 2.535 2.386 2.892 2.914 2.891 2.945 2.789 
VD = volume of distribution; MTD= Maximum Tolerated Dose; LD = Lethal Dose; TC = Total Clearence. 
 
Table 3: Antioxidant and antimitotic activities of 3 (a-k) 
Compound Antioxidant activity IC50 (mM) Antimitotic activity IC50 (mM) 
 3a 64.3 19 
3b 43.1 11 
3c 46 6 
3d 28 12 
3e 10 4 
3f 40 14 
3g 14 4 
3h 21 5 
3i 16 5 
3j 16 9 
3k 35 10 
Standard 21 (Ascorbic acid)  
 
Docking 
The synthesized molecules were docked into the same grid and 
checked for interactions with the receptor active sites and compared 
with the standard drug colchicine. The docking results are shown in 
table 4. The compounds were found to have binding energies in the 
range of-7.50 to-9.00 Kcal/mol for tubulin protein. All the 
compounds docked into the structure were deeply embedded into 
the hydrophobic pocket. The docking result indicating that H-bond 
interactions and hydrophobic interactions were important for the 
inhibition of tubulin protein, as shown in fig. 2. Among 11 
compounds, structures 3f, 3i, 3j and 3k were shown equivalent 
binding energies when compared with colchicine drug-8.7,-9,-8.7,-
8.6 and-8.6, respectively. Overall results demonstrating, cyclic 
compounds with two heteroatoms on the dithiocarbamate side 
chain were important for tubulin inhibition. 
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Hydrogen bond interactions Hydrophobic interactions 
3a -7.5 LEU B: 248  ALA A: 180, LYS B: 352, LEU B: 255, ALA B: 250, CYS B: 241 
3b -7.7 ASN A: 101 ALA A: 180, LYS B: 352, LEU B: 248, ALA B: 250, LYS B: 254 
3c -7.9 THR A: 179 ALA A: 180, LYS B: 352, LEU B: 255, ALA B: 250, CYS B: 241, ALA B: 316, 
LEU B: 248 
3d -7.5 THR A: 179, ASN A: 101 LEU B: 255,LYS B: 254,ALA A: 180, ALA B: 250, ALA B: 354, LUE B: 248, 
VAL A: 181, LYS B: 352 
3e -8.3 THR A: 179 LYS B: 352, CYS B: 241, LEU B: 248, LUE B: 255, ALA B: 250 
3f -8.7   ALA B: 316,ALA B: 354, VAL B: 318, LYS B: 254 
3g -7.9 SER A: 178 LEU B: 255,LYS B: 254,ALA B: 250, LEU B: 248, CYS B: 241, VAL B: 318, 
ALA B: 316, ALA B: 354 
3h -7.7 ASN B: 350, PRO B: 348. ASN B: 349 LEU B: 333 
3i -9  GTP A: 600, THR A: 179 ALA A: 180, ALA B: 250, LEU B: 255, LEU B: 248, LYS B: 352, CYS B: 241 
3j -8.7 ASN A: 101, ALA B: 250 ALA A: 180, LYS B: 352, LEU B: 255, LEU B: 248, CYS B: 241 
3k -8.6  TYR A: 224 ALA A: 180, LYS B: 352, LEU B: 248, ALA B: 250, CYS B: 241, LEU B: 255 
Colchicine -8.6 LYS B: 254, ASN A: 101, THR B: 353, 
LEU B: 248, LYS B: 352 
ALA B: 354 
 
 
Compound–3i     Compound–3j 
 
Compound–3k      colchicine 
Fig. 2: Dock poses of compound 3i, 3j, 3k and colchicine into Tubulin protein (1SA0) showing hydrogen bond interactions (▄ ▄ ▄) and 
Hydrophobic interactions (▄ ▄ ▄) 
 
CONCLUSION 
In the present study, we designed and synthesized a series of 
dithiocarbamate substituted phenothiazine derivatives. The 
derivatives were characterized by IR, 1H NMR, and HRMS. All the 
derivatives were screened for their antioxidant activity by the DPPH 
method, antimitotic activity using germinated Bengal gram seeds, 
and in silico experiments by various software. According to the 
results compounds 3e, 3g, 3i and 3j emerged as promising 
antioxidant agents. Further, compounds 3e, 3g, 3h, 3i, and 3j 
A. Kotha et al. 
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emerged as prominent antimitotic agents. From the in silico studies, 
all the compounds had drug-like properties and the best hit from 
auto dock vina are compounds 3f, 3i, 3j, and 3k when compared to 
colchicine, interacted prominently with the binding pocket of 
protein of tubulin receptor with remarkable hydrogen bonding and 
hydrophobic interactions. According to the docking scores, we 
suggest that compounds 3e are significantly active and this 
correlates with antioxidant and antimitotic activities. These 
interesting findings suggested that phenothiazine with 
dithiocarbamate as a side chain analog can serve as promising leads 
for inhibition of tubulin protein.  
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